English

Coeptis Therapeutics, Inc.

EDGAR

Quarterly report (10-Q) · filed 2022-11-08

13 filing records in this dataset, filed from 2020-10-20 to 2022-11-08. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2022 Q3 · USD

Exact inputs and evidence

Revenue: 0 USD Source

Operating cash flow

-1.03 million USD

2022 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -3028459 USD Source
Operating Cash Flow: -1995250 USD Source

Cash and cash equivalents: 4.94 thousand USD 2020-11-30 Source
Exact value

4938 USD
Long-term debt including current maturities: 150 thousand USD 2022-06-30 Source
Exact value

150000 USD
Shares outstanding: 43.2 million shares 2022-09-30 Source
Exact value

43207163 shares

Reported share-count change

24.33% · 8.46 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

34750733 shares · 2021-09-30· Source
43207163 shares · 2022-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

0 USD

2021-10-01 – 2022-09-30

Exact inputs and evidence

Revenue: 75000 USD · 2021-01-01 – 2021-12-31 Source
Revenue: 75000 USD · 2021-01-01 – 2021-09-30 Source
Revenue: 0 USD · 2022-01-01 – 2022-03-31 Source
Revenue: 0 USD · 2022-04-01 – 2022-06-30 Source
Revenue: 0 USD · 2022-07-01 – 2022-09-30 Source

Net income

-37.5 million USD

2021-10-01 – 2022-09-30

Exact inputs and evidence

Net income: -13449280 USD · 2021-01-01 – 2021-12-31 Source
Net income: -10609672 USD · 2021-01-01 – 2021-09-30 Source
Net income: -19179693 USD · 2022-01-01 – 2022-03-31 Source
Net income: -9802837 USD · 2022-04-01 – 2022-06-30 Source
Net income: -5648709 USD · 2022-07-01 – 2022-09-30 Source

Operating cash flow

-3.24 million USD

2021-10-01 – 2022-09-30

Exact inputs and evidence

Operating cash flow: -4489440 USD · 2021-01-01 – 2021-12-31 Source
Operating cash flow: -4280561 USD · 2021-01-01 – 2021-09-30 Source
Operating cash flow: -961729 USD · 2022-01-01 – 2022-03-31 Source
Operating cash flow: -1995250 USD · 2022-01-01 – 2022-06-30 Source
Operating cash flow: -961729 USD · 2022-01-01 – 2022-03-31 Source
Operating cash flow: -3028459 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -1995250 USD · 2022-01-01 – 2022-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2022-11-08.

Financial data available through: 2021-12-31.

Coverage by financial measure

Revenue: 2 of 11 periods available· newest 2021-12-31
Operating income: 2 of 11 periods available· newest 2021-12-31
Net income: 2 of 11 periods available· newest 2021-12-31
Operating cash flow: 2 of 11 periods available· newest 2021-12-31
Capital expenditure: 2 of 11 periods available· newest 2021-12-31
Total assets: 2 of 11 periods available· newest 2021-12-31
Total liabilities: 2 of 11 periods available· newest 2021-12-31
Current assets: 2 of 11 periods available· newest 2021-12-31
Current liabilities: 2 of 11 periods available· newest 2021-12-31
cash and cash equivalents: No compatible figures in this window
Long-term debt including current maturities: 1 of 11 periods available· newest 2021-12-31
Shares outstanding: 2 of 11 periods available· newest 2021-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+143.8%

Prior period

USD 30,761

2020-01-01 – 2020-12-31
Current period

USD 75,000

2021-01-01 – 2021-12-31

Exact inputs and evidence

75000 − 30761 = 44239 USD

30761 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
75000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Coeptis Therapeutics, Inc. · 2021-12-31 Coeptis Therapeutics, Inc. (edgar:1819663) Year-over-year change in Revenue: 44239 USD Concept: fundies:Revenue Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819663?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 75000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819663/000168316822001616/coeptis_i10k-123121.htm#490354 Filing: 000168316822001616 Input fundies:Revenue: 30761 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819663/000168316822001616/coeptis_i10k-123121.htm#490646 Filing: 000168316822001616
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 4.29 million

Prior period

−USD 9.16 million

2020-01-01 – 2020-12-31
Current period

−USD 13.45 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

-13449280 − -9156286 = -4292994 USD

-9156286 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
-13449280 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Coeptis Therapeutics, Inc. · 2021-12-31 Coeptis Therapeutics, Inc. (edgar:1819663) Year-over-year change in Net income: -4292994 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819663?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -13449280 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819663/000168316822001616/coeptis_i10k-123121.htm#593232 Filing: 000168316822001616 Input fundies:NetIncome: -9156286 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819663/000168316822001616/coeptis_i10k-123121.htm#593585 Filing: 000168316822001616
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 1.35 million

Prior period

−USD 3.14 million

2020-01-01 – 2020-12-31
Current period

−USD 4.49 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

-4489440 − -3136122 = -1353318 USD

-3136122 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
-4489440 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Coeptis Therapeutics, Inc. · 2021-12-31 Coeptis Therapeutics, Inc. (edgar:1819663) Year-over-year change in Operating cash flow: -1353318 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819663?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -4489440 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819663/000168316822001616/coeptis_i10k-123121.htm#609312 Filing: 000168316822001616 Input fundies:OperatingCashFlow: -3136122 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819663/000168316822001616/coeptis_i10k-123121.htm#609759 Filing: 000168316822001616
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
USD 0

Prior period

USD 0

2020-01-01 – 2020-12-31
Current period

USD 0

2021-01-01 – 2021-12-31

Exact inputs and evidence

-0 − -0 = 0 USD

-0 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
-0 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Coeptis Therapeutics, Inc. · 2021-12-31 Coeptis Therapeutics, Inc. (edgar:1819663) Year-over-year change in Capital expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819663?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: -0 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819663/000168316822001616/coeptis_i10k-123121.htm#612647 Filing: 000168316822001616 Input fundies:CapitalExpenditure: -0 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819663/000168316822001616/coeptis_i10k-123121.htm#613091 Filing: 000168316822001616
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2021 2021-01-01 – 2021-12-31

Revenue USD 75,000 100% of revenue
Cost of revenue USD 0 0% of revenue
Operating expenses USD 14.31 million 19,077% of revenue
Operating income −USD 14.23 million −18,977% of revenue
Tax, interest and other Derived −USD 783,786 −1,045% of revenue
Net income −USD 13.45 million −17,932% of revenue

Cash

Operating cash flow −USD 4.49 million −5,986% of revenue
Capital expenditure USD 0 −0% of revenue
Free cash flow Derived −USD 4.49 million −5,986% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2020 Operating loss: operating costs were 22,406% of revenue.
2021 Operating loss: operating costs were 19,077% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2020 2020-01-01 – 2020-12-31	30761	6892164 Derived	-6861403	2294883 Derived	-9156286	-3136122 Derived	Source 2020-01-01 – 2020-12-31: 30761 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -6861403 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -9156286 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -3136122 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: -0 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	75000	14308066 Derived	-14233066	-783786 Derived	-13449280	-4489440 Derived	Source 2021-01-01 – 2021-12-31: 75000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -14233066 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -13449280 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -4489440 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: -0 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 75K 2021

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Revenue	30761	Revenue: 30761 Open source
20212021-12-31	Revenue	75000	Revenue: 75000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

143.8% 2021

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Year over year	No prior comparable period	Revenue: 30761 Open source
20212021-12-31	Year over year	143.8%	Revenue: 75000 Open source Revenue: 30761 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -18,977.4% 2021

Net margin -17,932.4% 2021

Free cash flow margin -5,985.9% 2021

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Operating margin	-22,305.5%	Operating Income: -6861403 Open source Revenue: 30761 Open source
20212021-12-31	Operating margin	-18,977.4%	Operating Income: -14233066 Open source Revenue: 75000 Open source
20202020-12-31	Net margin	-29,765.9%	Net Income: -9156286 Open source Revenue: 30761 Open source
20212021-12-31	Net margin	-17,932.4%	Net Income: -13449280 Open source Revenue: 75000 Open source
20202020-12-31	Free cash flow margin	-10,195.1%	Revenue: 30761 Open source Operating Cash Flow: -3136122 Open source Capital Expenditure: -0 Open source
20212021-12-31	Free cash flow margin	-5,985.9%	Revenue: 75000 Open source Operating Cash Flow: -4489440 Open source Capital Expenditure: -0 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -4.5M 2021

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Operating cash flow	-3136122	Operating Cash Flow: -3136122 Open source
20212021-12-31	Operating cash flow	-4489440	Operating Cash Flow: -4489440 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -4.5M 2021

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Free cash flow	-3136122	Operating Cash Flow: -3136122 Open source Capital Expenditure: -0 Open source
20212021-12-31	Free cash flow	-4489440	Operating Cash Flow: -4489440 Open source Capital Expenditure: -0 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

65.3% 2021

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Liabilities / assets	1,811.7%	Total Liabilities: 5443827 Open source Total Assets: 300484 Open source
20212021-12-31	Liabilities / assets	65.3%	Total Liabilities: 4414942 Open source Total Assets: 6765576 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.79× 2021

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Current assets / current liabilities	0.04×	Current Assets: 224751 Open source Current Liabilities: 5279104 Open source
20212021-12-31	Current assets / current liabilities	0.79×	Current Assets: 2179558 Open source Current Liabilities: 2764942 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2020 2020-01-01 – 2020-12-31	−USD 9.16 million Exact value Exact value: -9156286 USD 2020-01-01 – 2020-12-31: -9156286 USD Inspect Net Income Open source Share or cite Citation for Net Income · Coeptis Therapeutics, Inc. · 2020-12-31 Coeptis Therapeutics, Inc. (edgar:1819663) Net Income: -9156286 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819663/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -9156286 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819663/000168316822001616/coeptis_i10k-123121.htm#593585 Filing: 000168316822001616 The citation records this snapshot. The page link may show a newer release later.	−USD 3.14 million Exact value Exact value: -3136122 USD 2020-01-01 – 2020-12-31: -3136122 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Coeptis Therapeutics, Inc. · 2020-12-31 Coeptis Therapeutics, Inc. (edgar:1819663) Operating Cash Flow: -3136122 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819663/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -3136122 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819663/000168316822001616/coeptis_i10k-123121.htm#609759 Filing: 000168316822001616 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: -0 USD 2020-01-01 – 2020-12-31: -0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Coeptis Therapeutics, Inc. · 2020-12-31 Coeptis Therapeutics, Inc. (edgar:1819663) Capital Expenditure: -0 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819663/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: -0 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819663/000168316822001616/coeptis_i10k-123121.htm#613091 Filing: 000168316822001616 The citation records this snapshot. The page link may show a newer release later.	−USD 3.14 million Calculation and evidence -3136122 − -0 USD Exact free cash flow: -3136122 USD 2020-01-01 – 2020-12-31: -3136122 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: -0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Coeptis Therapeutics, Inc. · 2020-12-31 Coeptis Therapeutics, Inc. (edgar:1819663) Free cash flow: -3136122 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819663?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -3136122 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819663/000168316822001616/coeptis_i10k-123121.htm#609759 Filing: 000168316822001616 Input fundies:CapitalExpenditure: -0 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819663/000168316822001616/coeptis_i10k-123121.htm#613091 Filing: 000168316822001616 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 13.45 million Exact value Exact value: -13449280 USD 2021-01-01 – 2021-12-31: -13449280 USD Inspect Net Income Open source Share or cite Citation for Net Income · Coeptis Therapeutics, Inc. · 2021-12-31 Coeptis Therapeutics, Inc. (edgar:1819663) Net Income: -13449280 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819663/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -13449280 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819663/000168316822001616/coeptis_i10k-123121.htm#593232 Filing: 000168316822001616 The citation records this snapshot. The page link may show a newer release later.	−USD 4.49 million Exact value Exact value: -4489440 USD 2021-01-01 – 2021-12-31: -4489440 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Coeptis Therapeutics, Inc. · 2021-12-31 Coeptis Therapeutics, Inc. (edgar:1819663) Operating Cash Flow: -4489440 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819663/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4489440 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819663/000168316822001616/coeptis_i10k-123121.htm#609312 Filing: 000168316822001616 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: -0 USD 2021-01-01 – 2021-12-31: -0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Coeptis Therapeutics, Inc. · 2021-12-31 Coeptis Therapeutics, Inc. (edgar:1819663) Capital Expenditure: -0 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819663/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: -0 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819663/000168316822001616/coeptis_i10k-123121.htm#612647 Filing: 000168316822001616 The citation records this snapshot. The page link may show a newer release later.	−USD 4.49 million Calculation and evidence -4489440 − -0 USD Exact free cash flow: -4489440 USD 2021-01-01 – 2021-12-31: -4489440 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: -0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Coeptis Therapeutics, Inc. · 2021-12-31 Coeptis Therapeutics, Inc. (edgar:1819663) Free cash flow: -4489440 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819663?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -4489440 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819663/000168316822001616/coeptis_i10k-123121.htm#609312 Filing: 000168316822001616 Input fundies:CapitalExpenditure: -0 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819663/000168316822001616/coeptis_i10k-123121.htm#612647 Filing: 000168316822001616 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

13 filings · 756 latest values · 756 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001819663, 1819663, edgar:1819663

Also known as COEPTIS THERAPEUTICS, INC., Coeptis Therapeutics Inc., Coeptis Therapeutics, Inc, Coeptis Therapeutics, Inc., VININGS HOLDINGS, INC., Vinings Holdings, Inc.

Coeptis Therapeutics, Inc.

Latest quarter

Revenue

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2021 2021-01-01 – 2021-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation